On Monday, B2Gold Corp (NYSEMKT:BTG)’s shares declined -3.03% to $1.60.
disclosed robust results from the Optimized Feasibility Study (OFS) of Fekola Gold Project (“Fekola Project”), commencement of construction at Fekola in Mali and the closing of the previously announced $350 million Revolving Credit Facility. All dollar figures are in United States dollars unless otherwise indicated. All Fekola Project amounts are on a 100% ownership basis.
Highlights of the Optimized Fekola Feasibility Study
- Open pit gold mine with an initial production life of mine (“LOM”) of 12.5 years based on probable mineral reserves
- Average annual gold production for years one through seven of 350,000 ounces per year at a $418 operating cash cost per ounce
- Average annual LOM gold production of 276,000 ounces per year at an operating cash cost of $552 per ounce
- New open pit probable mineral reserves of 49.2 million tonnes at a grade of 2.35 grams per tonne (“g/t”) gold containing 3.72 million ounces of gold at a stripping ratio of 4.5:1
- Average LOM gold recovery of 92.8% resulting in a total of 3.45 million ounces produced over the 12.5 year life of mine
B2Gold Corp., a mid-tier gold mining company, explores and develops mineral properties in Nicaragua, the Philippines, Namibia, Burkina Faso, and Chile. The company principally explores for gold, silver, and copper. It primarily holds a 100% interest in the La Libertad mine, which comprises of an exploitation concession covering 10,950 hectares located in Nicaragua; a 95% interest in the Limon mine property that covers an area of 12,000 hectares located northwest of Managua; and has 95% interest in Limon gold mine located in northwestern Nicaragua. The company also has interest in the Masbate mine, an open pit gold mine located near the northern tip of the island of Masbate; has a 90% interest in the Fekola gold mine located in southwestern Mali; and has 81% interest in the Kiaka gold project located in Burkina Faso. B2Gold Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
CBS Corporation (NYSE:CBS)’s shares dropped -0.60% to $58.14.
CBS Corporation (CBS) declared that its Board of Directors has approved a quarterly dividend on the Company’s stock of $.15 per share. The dividend is payable on July 1, 2015, to shareholders of record on June 10, 2015.
CBS Corporation operates as a mass media company worldwide. It operates through four segments: Entertainment, Cable Networks, Publishing, and Local Broadcasting. The Entertainment segment distributes a plan of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and distributes programming, counting series, specials, news, and public affairs; operates online content networks for information and entertainment; and produces, acquires, and distributes theatrical motion pictures.
At the end of Monday’s trade, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)‘s shares surged 1.17% to $0.285.
AEterna Zentaris Inc. (USA) (AEZS) declared that it has received written scientific advice from the European Medicines Agency (“EMA”) regarding the further development plan, counting the study design, for the new confirmatory Phase 3 clinical study of Macrilen™ (macimorelin) for use in evaluating adult growth hormone deficiency (“AGHD”), following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the Company believes that the confirmatory Phase 3 study that was talk about with the U.S. Food & Drug Administration (“FDA”) last March, meets the EMA’s study-design expectations.
Study design
The multinational confirmatory efficacy Phase 3 clinical study with Macrilen™ for the evaluation of AGHD will be conducted as a two-way crossover study with the insulin tolerance test as the benchmark comparator. The study population will comprise of patients with a medical history documenting risk factors for AGHD and will comprise a spectrum of patients from those with a low risk of having AGHD to those with a high risk of having the condition. The Company will submit a projected final protocol to the FDA for their review prior to commencing the confirmatory efficacy Phase 3 study. A dedicated thorough Phase 3 QT study to evaluate the effect of Macrilen™ on myocardial depolarization is predictable to be initiated in early 2016.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
CA, Inc. (NASDAQ:CA), ended its Monday’s trading session with -1.11% loss, and closed at $29.81.
CA Technologies (CA) has revealed Enterprise Big Data strategies are delivering key benefits to organizations despite noted challenges in implementation. Most notably, nine in 10 organizations are experiencing or anticipate seeing, more effective targeted marketing and selling campaigns. Additionally, 88 percent see or anticipate raised revenue. These benefits are impressive despite 92 percent of respondents citing obstacles to their Big Data projects.
The study, titled The State of Big Data Infrastructure: Benchmarking Global Big Data Users to Drive Future Performance, revealed the top five major obstacles to overcome for successful big data project implementation. These comprise: insufficient existing infrastructure (32 percent), organizational complexity (27 percent), security/compliance concerns (26 percent), lack of budget/resources (25 percent), and a lack of visibility into information and processes (25 percent).
Yet the benefits clearly outweigh the obstacles as 84 percent of large organizations have already, or plan to, implement a Big Data project within the next year. Managers cite improving customer experience (60 percent), acquiring customers (54 percent) and keeping up with competition (41 percent) as critical business factors and major drivers for deploying Big Data projects.
CA, Inc. provides information technology (IT) administration software and solutions that assist organizations plan, develop, manage, and secure applications and IT infrastructure in the United States and internationally. The company operates through three segments: Mainframe Solutions, Enterprise Solutions, and Services. The Mainframe Solutions segment’s products portfolio comprise systems and database administration, automation, application development, and security; and technologies comprise CA Application Lifecycle Conductor and vStorm Connect Data Streaming for big data. Its products are designed primarily for the IBM System z mainframe platform. The Enterprise Solutions segment provides products that operate primarily on non-mainframe platforms.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
